Front Immunol. 2022;13:1028102.

Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer.

, , , , , , , , , , ,

제1저자 김진영, 정지윤 · 교신저자 박완범, 이경훈

PMID 36466861 PMC9712216 DOI 10.3389/fimmu.2022.1028102 IF 7 감염내과

소속 (6)

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, South Korea.
Wide River Institute of Immunology, Seoul National University, Hongcheon, South Korea.
Department of Pharmacology, Seoul National University College of Medicine, Seoul, South Korea.
Cancer Research Institute, Seoul National University, Seoul, South Korea.

Abstract

INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants brought waves of pandemics with breakthrough infections in vaccinated individuals. We analyzed the antibody responses after primary and booster vaccination in healthy controls (HC) and patients with early breast cancer (BC).

METHODS In this prospective longitudinal cohort study, the binding activity of serum antibody level against spike proteins and antigens of SARS-CoV-2 variants was measured within 21 days after each vaccination in the BC group and HC group.

RESULTS All participants, 40 in the BC and 20 in the HC group, had increased antibody response after vaccination. BC group, however, had weaker humoral responses than the HC group (IgG: 1.5, 2.3, 2.5-folds in BC vs. 1.9, 3.6, 4.0-folds in HC after each dose; IgA: 2.1, 3.0, 3.6-folds in BC vs. 4.2, 10.4, 5.2-folds in HC after each dose, respectively). Those under concurrent cytotoxic chemotherapy had weaker antibody response than the non-cytotoxic treatment group and HC. Adjunct use of steroids and age were not significant risk factors. The levels of binding antibody against the Delta and the Omicron (BA1) variants were lower than the wild-type, especially in BC.

CONCLUSION In the waves of new sub-variants, our study suggests that an additional dose of vaccinations should be recommended according to the anti-cancer treatment modality in patients with BC who had received booster vaccination.

Keywords

COVID-19SARS-CoV-2adjuvant chemotherapybreast cancerneutralizing antibodiesserological response

Figures

**Figure 1** Antibody responses to SARS-CoV-2 nucleocapsid protein over time in breast cancer patients. Binding activities of IgG to SARS-CoV-2 nucleocapsid protein were determined using anti-IgG antibodies.

**Figure 2** Longitudinal humoral immune responses to SARS-CoV-2 spike D614G protein in breast cancer patients. **(A)** Serum IgG binding activities to SARS-CoV-2 spike D614G in healthy control group and breast cancer patients group were determined using anti-IgG antibodies. The diluted serum samples (1:10) were incubated with SARS-CoV-2 spike D614G protein and then detected by streptavidin-HRP. **(B–D)** Breast cancer patients were stratified by their age **(B)**, types of anti-cancer therapy **(C)**, and use of adjunct steroids **(D)**. **(E–H)** Serum IgA binding activities to SARS-CoV-2 spike D614G in the healthy control group and breast cancer patients group were determined using anti-IgA antibodies. **(F–H)** Breast cancer patients were stratified by their age **(F)**, types of anti-cancer therapy **(G)**, and use of adjunct steroids **(H)**. Statistical analyses were performed using the Multiple unpaired T-test in GraphPad Prism (**P <* 0.05, ***P <* 0.01, ****P <* 0.001, *****P <*0.0001).

**Figure 3** Longitudinal humoral immune response analysis to SARS-CoV-2 vaccine for SARS-CoV-2 VOCs. **(A–C)** Serum IgG binding activities against **(A)** RBD_wt, **(B)** RBD_δ, and **(C)** RBD_ο. **(D–F)** Serum IgA binding activities against **(D)** RBD_wt, **(E)** RBD_δ, and **(F)** RBD_ο. Binding activities of serum antibodies to RBD of SARS-CoV-2 variants were determined using anti-IgG or anti-IgA antibodies. In PBS, diluted plasma samples (1:100) were incubated with each biotinylated SARS-CoV-2 antigen and then detected by streptavidin-HRP. Statistical analyses were performed using the Multiple unpaired T-test in GraphPad Prism (**P <* 0.05, ***P <* 0.01, ****P <* 0.001, *****P <*0.0001).

그림 출처: PubMed Central 공개 논문 (PMC9712216)

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

그 밖의 정보